We are live on ! Find out more
RADX

Radiopharm Theranostics
RADX

6 hedge funds and large institutions have $1.18M invested in Radiopharm Theranostics in 2026 Q2 according to their latest regulatory filings, with funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

2.33% less ownership

Funds ownership: 650.86% → 648.52% (-2.3%)

14% less funds holding

Funds holding: 7 → 6 (-1)

43% less capital invested

Capital invested by funds: $2.06M → $1.18M (-$881K)

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
6
Holders Change
-1
Holders Change %
-14.29%
% of All Funds
0.07%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
3
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PNC Financial Services Group
PNC Financial Services Group
Pennsylvania
+$17.8K
2
HSBC Holdings
HSBC Holdings
United Kingdom
+$3.63K
3
RhumbLine Advisers
RhumbLine Advisers
Massachusetts
+$329

Top Sellers

Rank Fund Capital Flow
1
SCM
Silverarc Capital Management
Massachusetts
-$806K
2
UBS Group
UBS Group
Switzerland
-$6.64K

RADX Hedge Fund Activity: Q2 2026 in Review

6 of the 8,344 institutional investors tracked by Wall St. Rank reported a position in Radiopharm Theranostics (RADX) for Q2 2026, worth a combined $1.18M — down 43% from $2.06M a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of RADX and 0 opened new positions — a net loss of 1 holder — while 1 trimmed existing stakes and 3 added.

The largest buyer was PNC Financial Services Group, adding an estimated $17.8K. The largest seller was Silverarc Capital Management, exiting entirely with an estimated $806K sold.

  • 6 institutional investors held Radiopharm Theranostics (RADX) as of Q2 2026, down from 7 in Q1 2026.
  • Funds reported $1.18M of Radiopharm Theranostics stock for Q2 2026, down 43% quarter-over-quarter.
  • 0 funds opened new Radiopharm Theranostics positions in Q2 2026 and 1 closed out, a net change of -1 holder.
  • The largest Radiopharm Theranostics buyer in Q2 2026 was PNC Financial Services Group, an estimated $17.8K added.
  • The largest Radiopharm Theranostics seller in Q2 2026 was Silverarc Capital Management, an estimated $806K sold.

Based on aggregated 13F filings for Q2 2026.